Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...

Proprietary Insights – Stifel Discover delivers exclusive analysis and commentary from Stifel’s Chief Investment Officer, Chief Economist, Chief Washington Policy Strategist, equity research analysts, ...

In a report released today, Benjamin Burnett from Stifel Nicolaus maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), ...

Stifel analysts reaffirmed their Buy rating on Generac Holdings (NYSE:GNRC) with a consistent price target of $210.00. Currently trading at $145.07 with a market capitalization of $8.63 billion, ...

Ron Kruszewski, Stifel's chairman and CEO, told financial analysts that its investment banking franchise is well-positioned ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr Joel ...

Q4 2024 Earnings Conference Call January 29, 2025 9:30 AM ETCompany ParticipantsJoel Jeffrey - Senior Vice President ...

On Monday, Stifel analysts maintained a Buy rating on ServiceTitan stock (NASDAQ:TTAN) with a steady price target of $120.00. The company, currently trading at $92.56 with a market capitalization ...